Allergan Transfers Restasis Patents To IPR-Immune Tribe

Law360, New York (September 8, 2017, 6:39 PM EDT) -- Allergan PLC has transferred the patents for its dry eye treatment Restasis to a Native American tribe with sovereign immunity in a bid to escape inter partes review proceedings before the Patent Trial and Appeal Board, the pharmaceutical company said Friday.

The Saint Regis Mohawk Tribe gave Allergan back the exclusive licenses related to the drugmaker's highly profitable eye drops — which generated about $1.5 billion in revenue for the company in 2016 — and is filing a motion to toss the ongoing inter partes review of the patents based on its status as a sovereign tribal government. In turn, Allergan is paying the...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS